The Filing Desk

Inhibrx Biosciences vs Z Squared

Inhibrx Biosciences INBX · Z Squared ZSQR · Biotechnology

Z Squared reported revenue of $1 million in fiscal 2025, about the same as Inhibrx Biosciences' $1 million in fiscal 2025. Inhibrx Biosciences had an operating margin of -10386.5%, against -956.9% at Z Squared.

Side by side

Inhibrx BiosciencesZ Squared
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$1M$1M
Revenue growth550.0%—
Revenue growth a year, last 5 years——
Gross margin—86.8%
Operating margin−10,386.5%−956.9%
Net margin−10,773.5%−874.3%
Free cash flow−$130M—
Free cash flow margin−9,986.5%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count3.4%120.0%
Last close$83.30$2.38
P/E at the last close——
Insider trades, last 12 months—bought $3,920, sold $0
Piotroski F-score2 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Inhibrx BiosciencesZ Squared
Operating margin
Percent of revenue
Inhibrx BiosciencesZ Squared
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Inhibrx BiosciencesZ Squared

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Inhibrx Biosciences and Z Squared pages.